Bone loss induced by cancer treatment and its management

European Journal of Cancer

Volumn 34, Issue 2, 1998, Pages 260-262

  Delmas, P D ^a   Fontana, A ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; GLUCOCORTICOID; PAMIDRONIC ACID; PARATHYROID HORMONE RELATED PROTEIN; RISEDRONIC ACID; TAMOXIFEN; THYROXINE;

ARTICLE; BONE ATROPHY; BONE METABOLISM; BONE PAIN; BREAST CANCER; CANCER CHEMOTHERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS INHIBITION; OSTEOPOROSIS; PRIORITY JOURNAL; STEROID THERAPY;

EID: 0032512906     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)10135-6     Document Type: Article

References (21)

1. 1. Friedlaender GE, Tross RB, Doganis AC, et al. Effects of chemotherapeutic agents on bone. J Bone Joint Surg 1984, 66A, 602-607.
2. 2. Diamond T, Nery L, Hales I. A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma. J Clin Endocrinol Metab 1990, 72, 1184-1188.
3. 3. Uzzan B, Campos J, Cucherat M, et al. Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab 1996, 81, 4278-4289.
4. 4. Lukert BP. Glucocorticoid and drug-induced osteoporosis. In Favus MJ. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Philadelphia, New York, Lippincott-Raven. Third edn, 278-282.
5. 5. Stepan J, Lachman M, Zverina J, et al. Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. J Clin Endocrinol Metab 1989, 69, 523-527.
6. 6. Holmes SJ, Whitehouse RW, Clark ST, et al. Reduced bone mineral density in men following chemotherapy for Hodgkin's disease. Br J Cancer 1994, 70, 371-375.
7. 7. Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol 1997, 157, 439-444.
8. 8. Redman JR, Bajorunas DR, Wong G, et al. Bone mineralization in women following successful treatment of Hodgkin disease. Am J Med 1988, 86, 65-72.
9. 9. Chapman RM, Sutcliffe SB. Protection of ovarian function by oral contraceptives in women receiving chemotherapy for Hodgkin disease. Blood 1981, 58, 849-851.
10. 10. Delmas PD, Hormone replacement therapy in the prevention and treatment of osteoporosis. Osteoporosis Int 1997, 7, Suppl. 1, S3-S7.
11. 11. Bruning PF, Pit MJ, de Jong-Bakker M, et al. Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. Br J Cancer 1990, 61, 308-310.
12. 12. Powles TJ, Hickish T, Kanis JA, et al. Effect of tamoxifen on bone mineral density measured by dual energy X-Ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996, 14, 78-84.
13. 13. Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992, 326, 852-856.
14. 14. Delmas PD, Balena R, Confavreux E, et al. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double blind, placebo-controlled study. J Clin Oncol 1997, 15, 955-962.
15. 15. Hortobagy GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastase. N Engl J Med 1996, 335, 1785-1791.
16. 16. Paterson AHG, Powles TJ, Kanis JA, et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993, 11, 59-65.
17. 17. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996, 334, 488-493.
18. 18. Rauschining W, Pritchard KI. Droloxifen, a new antiestrogen/its role in metastatic breast cancer. Breast Cancer Res Treat 1994, 31, 83-94.
19. 19. Coombes RC, Haynes BP, Dowset M, et al. Idoxifen: report of a phase I study in patients with metastatic breast cancer. Cancer Res 1995, 55, 1070-1074.
20. 20. Black LJ, Sato M, Rowley ER, et al. Raloxifene (LY 139481 HCL) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 1994, 93, 63-69.
21. 21. Delmas PD, Bjarnason NH, Mitlak BH, et al. The effects of raloxifene on bone mineral density, serum cholesterol, and uterine endometrium in postmenopausal women. N Engl J Med 1997, 337, 1641-1647.